Overview

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).
Phase:
Phase 2
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Ethanol
Olanzapine